Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
4-20-2022

The impact of implementing the Virtuo blood culture system on
the characteristics and management of patients with
Staphylococcus aureus bacteremia
Miguel A Chavez
Washington University School of Medicine in St. Louis

Satish Munigala
Washington University School of Medicine in St. Louis

Carey-Ann D Burnham
Washington University School of Medicine in St. Louis

Melanie L Yarbrough
Washington University School of Medicine in St. Louis

David K Warren
Washington University School of Medicine in St. Louis

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Chavez, Miguel A; Munigala, Satish; Burnham, Carey-Ann D; Yarbrough, Melanie L; and Warren, David K,
,"The impact of implementing the Virtuo blood culture system on the characteristics and management of
patients with Staphylococcus aureus bacteremia." Journal of clinical microbiology. 60,4. . (2022).
https://digitalcommons.wustl.edu/open_access_pubs/11924

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

BACTERIOLOGY

The Impact of Implementing the Virtuo Blood Culture System
on the Characteristics and Management of Patients with
Staphylococcus aureus Bacteremia
Miguel A. Chavez,a Satish Munigala,a

Carey-Ann D. Burnham,b

Melanie L. Yarbrough,b

David K. Warrena

Department of Medicine, Division of Infectious Diseases, Washington University School of Medicine, St. Louis, Missouri, USA

a

Department of Pathology & Immunology, Division of Laboratory and Genomic Medicine, Washington University School of Medicine, St. Louis, Missouri, USA

b

Persistent Staphylococcus aureus bacteremia (SAB) has been associated
with increased mortality. Enhanced microbial detection with new blood culture technology may improve detection of S. aureus in patients with SAB. We performed a 24-month
retrospective study of hospitalized adults with SAB and an infectious diseases consult
comparing two time periods pre- (January to December 2018) and postimplementation
(January to December 2019) in which the VersaTREK and BacT/Alert Virtuo blood culture
systems were used, respectively. Measurements included SAB duration, time to positivity,
source of bacteremia, antimicrobial therapy, and mortality. A total of 416 episodes of
SAB occurred during the study period: 176 (42%) pre- and 240 (58%) postimplementation. Patients in both periods had similar clinical characteristics; however, patients in the
postimplementation period were more likely to have intermediate (3 to 6 days; 23% versus 40%; P , 0.001) and prolonged SAB duration (.7 days; 4% versus 14%; P , 0.001).
Combination antistaphylococcal therapy was more frequent postimplementation (6.3%
pre- versus 15.8% postimplementation; P = 0.003), and the median time to source control was shorter (4 versus 2 days; P = 0.02). Median time to positivity for the index blood
culture was shorter postimplementation (17.8 h pre- versus 13.3 h postimplementation;
P , 0.001). There was no difference in 90-day all-cause readmissions (51% versus 44%;
P = 0.11) or mortality (32% versus 32%; P = 0.95). An increased frequency of prolonged
SAB with increased use of combination antistaphylococcal therapy was noted with
implementation of a new blood culture system, likely secondary to the blood culture
media; however, no differences on adverse outcomes were noted.

KEYWORDS S. aureus, bacteremia, blood culture, staphylococcal infections, treatment

outcome

S

taphylococcus aureus bacteremia (SAB) is a common community- and hospital-onset
bloodstream infection (BSI) and is associated with signiﬁcant morbidity and mortality (1,
2). Delays in diagnosis and appropriate therapy can lead to serious complications, such as
endocarditis, osteomyelitis, and death. Several studies have identiﬁed persistent bacteremia
to be associated with prolonged hospital length of stay, increased risk of embolic complications, and mortality (1, 3). Despite this, randomized trials have failed to ﬁnd an association
between earlier clearance of blood cultures with the use of combination antibiotic therapy
and reduced mortality (4). Similarly, the time to blood culture positivity (TTP) has been considered an independent predictor of infective endocarditis and even death (5, 6). While TTP
is often thought by clinicians to represent the burden of bacteria and the microbial growth
rate in the blood sample, many factors can inﬂuence TTP, such as the culture media used,
the blood volume collected, and the presence of antibiotics in the blood specimen (7, 8).
Newer blood culture systems have been developed with the goal of providing
more rapid detection of microorganisms in the setting of BSI (9). Newer formulations
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of blood culture media, coupled with updated instrumentation algorithms, may allow
for faster bacterial growth and inactivation of antibiotics present in the blood, resulting
in faster time to detection of microbial growth and possibly higher rate of organism recovery (10). Previous studies have shown that detection rate and TTP can vary among
blood cultures systems, especially in the presence of antibiotics (8, 11). The objective
of our study was to determine the impact of implementation of the BacT/Alert Virtuo
blood culture system (Virtuo; bioMérieux, Durham, NC) on the microbiological characteristics and management of SAB at our institution.

Setting and study design. We performed a retrospective cohort study of adults hospitalized with
SAB at Barnes-Jewish Hospital (BJH), a 1,250-bed academic hospital in St. Louis, Missouri, USA. Starting
14 January 2019, our institution implemented the Virtuo system (bioMérieux, Durham, NC) in replacement of the VersaTREK system (TREK Diagnostic Systems, Cleveland, OH) for analysis of blood cultures.
We divided our cohort into SAB episodes using their initial positive, or index, blood culture in the preimplementation (VersaTREK; 1 January 2018 to 13 January 2019) and postimplementation (Virtuo; 14
January 2019 to 31 December 2019) periods. All episodes of SAB in patients .18 years of age were identiﬁed using the BJH medical informatics database. We excluded SAB episodes in patients that died within
48 h after the index blood culture and with recurrent episodes occurring within 90 days of the index blood
culture. To standardize the management of SAB throughout the study period, we also excluded patients
without an infectious diseases (ID) consult. We did not exclude patients transferred from other hospitals,
patients that received antibiotics prior to blood culture collection, or patients with polymicrobial BSI. The
study was approved by the Washington University School of Medicine Institutional Review Board with a
waiver of informed consent.
Blood culture systems. During the preimplementation period, the VersaTREK system was used with
VersaTREK REDOX 1 (aerobic) and REDOX2 (anaerobic) media, which utilized a 1:9 blood/broth dilution
to neutralize the effects of antibiotics if present. In the postimplementation period, the Virtuo system
was used with FA Plus (aerobic) and FN Plus (anaerobic) media that have polymeric resins that inhibit
antibiotics if present in the blood. During both time periods, sampling for suspected bacteremia was
standard and included obtaining at least two sets of aerobic and anaerobic bottles from two separate
phlebotomy sites. The requested blood volume per blood culture set was 20 mL, divided equally into
the aerobic and anaerobic bottles. Obtaining only one set of aerobic and anaerobic bottles in a day or
more than one set from a single phlebotomy site or blood sampling from a central line is discouraged.
No guidelines exist at our institution regarding the frequency of repeat blood cultures to document
clearance, and it is left to the discretion of the clinician. During both time periods, the laboratory loaded
blood cultures onto the instrument and processed positive blood cultures 24 h per day, 7 days per
week. The incubation period for both systems was up to 5 days or until the blood culture bottle signaled
positive for growth. Positive bottles were processed according to laboratory standard operating procedure (12). Final organism identiﬁcation was made using matrix assisted laser desorption ionization-time
of ﬂight mass spectrometry (MALDI-TOF MS) (Bruker BioTyper, Bruker Daltonics).
Deﬁnitions and study outcomes. A SAB episode was deﬁned as a patient having S. aureus isolated
from at least one blood culture bottle. Determination of methicillin susceptibility of Staphylococcus aureus isolates was performed using the Kirby-Bauer disk diffusion method (cefoxitin) in accordance with
CLSI standards.
We deﬁned SAB duration as the number of days between the ﬁrst and last positive blood culture
with S. aureus. We then divided SAB duration as being short (1 to 2 days), intermediate (3 to 6 days), or
prolonged ($7 days) (3, 13). For the multivariate analyses, we deﬁned persistent bacteremia as $3 days
of positive blood cultures, based on previous studies that found this duration of bacteremia to be associated with increased mortality (3). Community-onset SAB was deﬁned as the ﬁrst positive blood culture
collected within 48 h of hospital admission; otherwise, it was classiﬁed as hospital-onset SAB. TTP was
deﬁned as the time from the blood culture bottle being loaded on the instrument until detection as positive by the instrument. We used the shortest TTP if more than one blood culture was positive for S. aureus during that day.
The electronic medical records for all SAB episodes were reviewed for demographic variables, ID consultation notes, antibiotic management, echocardiography and imaging studies, and any surgical procedures
done for source control, including hardware removal, incision and drainage, etc. Combination antistaphylococcal therapy was deﬁned as use of .1 active antistaphylococcal agent for the treatment of SAB, and
not for coverage of a different organism, based upon ID consultation recommendations at any time during
treatment. Deﬁnitive antibiotic therapy was deﬁned as antibiotic chosen at discharge and/or ﬁnal antibiotic
recommendations by the ID consultant. Final diagnoses, infectious complications, and recommended antibiotic duration were obtained from the ID consultation notes. All-cause 90-day mortality, all-cause 90-day
readmission rate, and length of stay in the index hospital stay for the SAB episode were obtained from the
medical records.
Statistical analysis. Continuous variables were expressed as medians with interquartile ranges, as
appropriate, and assessed using the Mann-Whitney U test. Categorical variables were presented as absolute numbers and frequencies and were compared using chi-square test or Fisher’s exact test, as appropriate. We used a two-sided P value of ,0.05 as a statistically signiﬁcant result. Variables with a known
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RESULTS
Study population. A total of 479 SAB episodes were identiﬁed in 456 patients during the study period. Twenty-three (5%) were episodes with recurrence of SAB within
90 days of index episode, four (0.8%) patients died within 48 h after index blood culture, and 36 episodes (8% overall; 7.3% pre- versus 8.3% postimplementation; P = 0.68)
did not have ID consultation. One patient had an episode of SAB .90 days after the
index positive blood culture, which was considered a separate episode for purposes of
analysis. Thus, a total of 416 episodes in 415 patients were included for analyses: 176
(42%) pre- and 240 (58%) postimplementation. The median age of patients was
58 years, 60% were male, 40% had methicillin-resistant Staphylococcus aureus (MRSA)
bacteremia, and 68% were community-onset infections. Clinical characteristics were
similar between both periods, except there were more episodes of catheter-related BSI
on the preimplementation period (P = 0.046) (Table 1).
Blood culture collection and TTP. During both periods, two sets of aerobic and anaerobic bottles were collected for each day of blood culture collection (median 2 sets
[interquartile range {IQR} 2 to 2] preimplementation versus 2 sets [IQR 2 to 2] postimplementation; P = 0.95), and these were collected on average every 28 h (IQR 23 to 39)
in the preimplementation and every 26 h (IQR 23 to 32) in the postimplementation period (P = 0.058).
The median TTP for the index blood culture was shorter in the postimplementation
period (17.8 [IQR 14 to 23] h pre- versus 13.3 [IQR 10 to 19] h postimplementation,
P , 0.001), and this difference remained statistically signiﬁcant up until day 5 of bacteremia. During the postimplementation period, the TTP remained similar on the following days after index blood culture compared to a longer TTP during the ﬁrst 4 days
in the preimplementation period (Fig. 1). A shorter TTP in the index blood culture was
a predictor of persistent SAB in the multivariable logistic model (odds ratio [OR] of 0.95
[95% conﬁdence interval {CI} of 0.93 to 0.98]; P = 0.001) (Table 2) and remained signiﬁcant in the postimplementation period using the Virtuo system (supplemental
material).
Duration of bacteremia. Episodes had a median duration of SAB of 2 days (range, 1 to
14 days). Postimplementation, episodes had longer median SAB duration (1 [IQR 1 to 3] day
pre- versus 3 [IQR 1 to 5] days postimplementation, P , 0.001) and were more likely to
have intermediate (23% pre- versus 40% postimplementation; P , 0.001) and prolonged
SAB duration (4% pre- versus 14% postimplementation; P , 0.001). By multivariable analysis, the use of Virtuo system during the postimplementation period was associated with persistent SAB (OR 3.2 [95% conﬁdence interval {CI} 1.97 to 5.2]; P , 0.001) (Table 2).
SAB management. Echocardiography and imaging studies were ordered equally
during both study periods, except for ﬂuorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) scans, which were obtained more frequently
during the postimplementation period (1% pre- versus 5% postimplementation;
P = 0.004) (Table 1). These studies, with the exception of transthoracic echocardiography, were obtained more frequently among patients with a longer duration of SAB,
regardless of study period (short, intermediate, and prolonged SAB; transesophageal
echocardiography: 21%, 38%, and 65%, respectively; P , 0.001; computed tomography
of chest, abdomen, and pelvis: 13%, 21%, 53%, respectively; P , 0.001; magnetic resonance imaging of the spine: 12%, 20%, 43%, respectively; P , 0.001; FDG-PET/CT: 0%,
3%, 23%, respectively; P , 0.001).
The proportion of patients undergoing procedures to achieve source control was
similar in both periods (P = 0.81), but the median time from index blood culture to
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increased mortality risk, based on previously published studies, and variables with clinical plausibility
were screened for an association with prolonged SAB and all-cause 90-day mortality. A stepwise backwards logistic regression model was performed using variables that had a P value of ,0.1 on bivariate
analysis. Variables were retained in the ﬁnal model if they had a P value of ,0.05. Odds ratios (OR) were
calculated for the logistic regression model with 95% conﬁdence intervals. We assessed multicollinearity
of variables, based on the variance inﬂation factor, and none were present. Analysis was performed with
the use of STATA software version 16.1 (StataCorp, TX, USA).
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Variable, n (%) or median (IQR)
Age, yrs
Sex, male
Charlson comorbidity index
ICU admission within 48 hours after index BC
ICU admission during hospitalization
MRSA bacteremia
Bacteremia onset, community-onset

Preimplementationb
(n = 176)
57 (46–69)
100 (57)
5 (3–8)
81 (46)
97 (55)
79 (45)
122 (69)

Postimplementationc
(n = 240)
58 (43–69)
149 (62)
5 (3–8)
113 (47)
134 (56)
89 (37)
161 (67)

P value
0.92
0.28
0.92
0.83
0.88
0.11
0.63

Site of infection
Isolated bacteremia
Central line-associated bacteremia
Skin and soft tissue infection
Osteomyelitis
Septic arthritis
Epidural abscess
Endocarditis
Vascular graft infection
Lower respiratory tract infection
Cardiac device associated infection

35 (20)
50 (28)
23 (13)
24 (14)
12 (7)
8 (5)
28 (16)
5 (3)
18 (10)
10 (6)

53 (22)
48 (20)
31 (13)
30 (13)
16 (7)
5 (2)
40 (17)
9 (4)
28 (12)
10 (4)

0.59
0.046
0.96
0.73
0.95
0.17
0.84
0.79
0.64
0.48

Bacteremia duration, days
Short (1–2 days)
Intermediate (3–6 days)
Prolonged (.7 days)

1 (1–3)
129 (73)
40 (23)
7 (4)

3 (1–5)
110 (46)
97 (40)
33 (14)

,0.001
,0.001
,0.001
,0.001

MSSA, bacteremia duration
Short (1–2 days)
Intermediate (3–6 days)
Prolonged (.7 days)

80 (82)
15 (15)
2 (2)

79 (52)
57 (38)
15 (10)

,0.001
,0.001
,0.001

MRSA, bacteremia duration
Short (1–2 days)
Intermediate (3–6 days)
Prolonged (.7 days)

49 (62)
25 (32)
5 (6)

31 (35)
40 (45)
18 (20)

0.001
0.001
0.001

Removable source of infection
Source removed/controlled

109 (62)
82 (75)

149 (63)
109 (73)

0.86
0.74

Time from index BC to source control, days
Transthoracic echocardiography
Transesophageal echocardiography
Spinal MRI
CT chest/abdomen/pelvis
FDG-PET/CT

4 (2–6)
170 (97)
48 (27)
36 (20)
27 (15)
1 (1)

2 (1–6)
231 (96)
80 (33)
38 (16)
53 (22)
13 (5)

0.02
0.85
0.19
0.22
0.1
0.005

Outcomes
Hospital length of stay, days
90-day all-cause readmission
90-day all-cause mortality

16 (8–28)
91 (52)
57 (32)

17 (9–31)
105 (44)
77 (32)

0.29
0.11
0.95

aIQR,

interquartile range; MRSA, methicillin-resistant S. aureus; MSSA, methicillin-susceptible S. aureus; BC, blood culture; MRI, magnetic resonance imaging; CT, computed
tomography; FDG-PET/CT, ﬂuorodeoxyglucose-positron emission tomography/computed tomography.
b
Preimplementation period from 1 January 2018 to 13 January 2019.
cPostimplementation period from 14 January 2019 to 31 December 2019.

source control was shorter in the postimplementation period (4 [IQR 2 to 6] days preversus 2 [1 to 6] days postimplementation; P = 0.02) (Table 1). A longer time to source
control was observed based on duration of bacteremia, regardless of study period
(short, intermediate, and prolonged: 2, 4, 10 days, respectively, P = 0.004).
Vancomycin was the most common antibiotic used as initial and deﬁnitive therapy
during both periods but was used less frequently as deﬁnitive therapy in the postimplementation period. None of the antibiotics used as initial therapy were associated
with persistent SAB in the multivariate analysis (Table 2). Linezolid, ceftaroline,
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TABLE 1 Clinical characteristics and outcomes of 416 Staphylococcus aureus bacteremia episodes by intervention perioda
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cefazolin, and antistaphylococcal penicillins were used signiﬁcantly more often in the
postimplementation period as deﬁnitive therapy (Table 3). Combination antistaphylococcal therapy was used more frequently in the postimplementation period (6% preversus 16% postimplementation; P = 0.003), with daptomycin plus ceftaroline being
the most frequent combination therapy (Table 3). Patients with longer durations of
SAB were more likely to have received combination antistaphylococcal therapy, across
both study periods (short, intermediate, and prolonged; 3%, 14%, and 58%, respectively; P , 0.001). The median planned duration of intravenous antibiotics did not vary
between pre- and postimplementation periods (6 [4 to 6] weeks pre- versus 6 [4 to 6]
weeks postimplementation, P = 0.32).
Clinical outcomes. The median hospital length of stay (16 [IQR 8 to 28] days preversus 17 [9 to 31] days postimplementation; P = 0.29), 90-day all-cause readmissions
(52% pre- versus 44% postimplementation; P = 0.11), and 90-day all-cause mortality
(32% pre- versus 32% postimplementation; P = 0.95) did not differ between study periods. These outcomes were not signiﬁcantly different by duration of bacteremia in either study period.
Predictors of mortality. Age, lower respiratory tract infection, and linezolid use
were predictors of increased all-cause 90-day mortality, while osteomyelitis had
decreased risk of 90-day mortality in the ﬁnal prediction model (Table 4), showing an
acceptable goodness-of-ﬁt measured by the Hosmer-Lemeshow test ( x 2-statistic = 7.18,
P = 0.52).
DISCUSSION
Blood cultures are an important aspect of SAB diagnosis and management, with
clearance of bacteremia being one of the immediate goals of therapy. In our study, after our laboratory implemented the Virtuo system, we observed an increased frequency of persistent SAB ($3 days) and shorter TTP of blood cultures compared to
those observed with the previous blood culture system. SAB episodes in the postimplementation period were associated with an increased use of FDG-PET/CT scans and
combination antistaphylococcal therapy, plus a shorter time to source control, without
a signiﬁcant change in mortality or readmissions compared to those of SAB episodes in
the preimplementation period.
April 2022 Volume 60 Issue 4
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FIG 1 Median time to positivity (hours) by day of blood culture, by study period. *, Compares median time to positivity
between pre- and postimplementation periods in any given day. †, Preimplementation period from 1 January 2018 to 13
January 2019. ‡, Postimplementation period from 14 January 2019 to 31 December 2019. BC, blood culture.
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TABLE 2 Bivariate and multivariate analyses of factors associated with persistent bacteremia among 416 Staphylococcus aureus bacteremia
episodesa
Variable, n (%) or median (IQR)
Age, yrs
Sex, male
Charlson comorbidity index
ICU admission within 48 hours of index BC
ICU admission during hospitalization
MRSA bacteremia
Bacteremia onset, community-onset
Postimplementation period

Short bacteremia
(n = 239)
57 (43–68)
145 (61)
5 (3–8)
109 (46)
128 (54)
80 (33)
146 (61)
110 (46)

Intermediate-prolonged
bacteremia (n = 177)
59 (44–70)
104 (59)
5 (3–8)
85 (48)
103 (58)
88 (50)
137 (77)
130 (74)

Crude OR (95% CI)
1.01 (0.99–1.02)
0.92 (0.62–1.37)
1.02 (0.96–1.09)
1.11 (0.75–1.63)
1.21 (0.82–1.79)
1.97 (1.32–2.93)
2.18 (1.41–3.38)
3.24 (2.13–4.93)

Site of infection
Isolated bacteremia
Central line-associated bacteremia
Skin and soft tissue infection
Osteomyelitis
Septic arthritis
Epidural abscess
Endocarditis
Vascular graft infection
Lower respiratory tract infection
Cardiac device associated infection

58 (24)
69 (29)
30 (13)
22 (9)
11 (5)
4 (2)
25 (10)
6 (3)
29 (12)
12 (5)

30 (17)
29 (16)
24 (14)
32 (18)
17 (10)
9 (5)
43 (24)
8 (5)
17 (10)
8 (5)

0.64 (0.39–1.04)
0.48 (0.30–0.79)
1.09 (0.61–1.94)
2.17 (1.22–3.9)
2.2 (1.0–4.83)
3.15 (0.95–10.4)
2.75 (1.6–4.7)
1.84 (0.63–5.4)
0.77 (0.41–1.45)
0.9 (0.36–2.24)

Time to positivity of index BC, h
Source removed/controlled
Time from index BC to source control, daysc

19 (15–24)
113 (47)
2 (1–5)

14.7 (12–19)
78 (44)
4 (1–10)

0.94 (0.92–0.97)
0.88 (0.59–1.3)
1.08 (1.02–1.14)

Initial antistaphylococcal therapy
Vancomycin
Daptomycin
Linezolid
Cefazolin
Antistaphylococcal penicillin

188 (79)
3 (1)
14 (6)
6 (3)
4 (2)

142 (80)
4 (2)
7 (4)
3 (2)
4 (2)

1.1 (0.7–1.78)
1.82 (0.4–8.2)
0.66 (0.26–1.68)
0.67 (0.17–2.71)
1.36 (0.34–5.51)

Adjusted ORb
(95% CI)

2.66 (1.68–4.21)
1.7 (1.04–2.77)
3.2 (1.97–5.2)

2.73 (1.1–6.77)
4.47 (1.19–16.8)
2.82 (1.51–5.26)

0.95 (0.93–0.98)

aIQR,

interquartile range; OR, odds ratio; CI, conﬁdence intervals; BC, blood culture; ICU, intensive care unit; MRSA, methicillin-resistant S. aureus.
included in the ﬁnal logistic regression model were MRSA bacteremia, bacteremia onset, postimplementation period, isolated bacteremia, central line-associated
bacteremia, osteomyelitis, septic arthritis, epidural abscess, endocarditis, and time to positivity of index BC.
cTime from index BC to source control included 191 Staphylococcus aureus bacteremia episodes and was analyzed in a different logistic regression model (supplemental
material).

Previous studies have shown detection rates of S. aureus with the Virtuo system
similar to those with other blood culture systems (11, 14–20). However, in the presence
of antibiotics, other commercially available blood cultures systems showed better recovery rate than the VersaTREK system (21, 22). Our group has previously reported that
the blood cultures performed on the Virtuo system had a positivity rate for S. aureus recovery overall higher than that of the VersaTREK system (1.5% pre- versus 3.4% postimplementation, P , 0.001) during the same study period (10). Interestingly, we found
that the use of Virtuo system in the postimplementation period was independently
associated with a longer duration of bacteremia, despite patients having similar clinical
characteristics and outcomes, and similar frequency and number of blood culture bottles collected. To our knowledge, this is the ﬁrst study to demonstrate that a new blood
culture system may increase observed SAB duration and, thus, possibly inﬂuence SAB
management due to the perception of failing to clear blood cultures. In previous studies, resin-based media showed an advantage in inhibition of antibiotics (23), and it is
possible that the resins present in the FA Plus and FN Plus media of the Virtuo system
inhibited antibiotic activity in the blood samples better than the REDOX 1 and 2 media
from the VersaTREK system, increasing recovery of S. aureus from blood specimens despite patients being on appropriate antibiotic therapy. Thus, we believe that the media
composition, rather than the instrument itself, was the principal factor affecting recovery of S. aureus in the subsequent repeat blood cultures, causing an increase of the
overall positivity rate and longer observed duration of SAB. However, we cannot rule
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TABLE 3 Antibiotic therapy of 416 Staphylococcus aureus bacteremia episodes, by study
period
Preimplementation
(n = 176)a

Postimplementation
(n = 240)b

P value

133 (76)
5 (3)
8 (5)
2 (1)
2 (1)
11 (6)
2 (1)
0 (0)

197 (82)
2 (1)
13 (5)
4 (2)
7 (3)
14 (6)
6 (3)
2 (1)

0.11
0.12
0.69
0.65
0.31
0.86
0.48
0.34

Deﬁnitive antibiotic therapyd
Vancomycin
Daptomycin
Linezolid
Ceftaroline
Cefazolin
Ceftriaxone
Antistaphylococcal penicillin

61 (35)
19 (11)
2 (1)
11 (6)
27 (14)
41 (23)
21 (12)

52 (22)
36 (15)
11 (5)
33 (14)
58 (24)
38 (16)
47 (20)

0.003
0.21
0.05
0.01
0.027
0.055
0.037

Combination antistaphylococcal therapy
Daptomycin-ceftaroline
Vancomycin-ceftaroline
Vancomycin- b -lactams
Other combinations

11 (6)
6 (3)
2 (1)
2 (1)
1 (1)

38 (16)
23 (10)
5 (2)
10 (4)
0 (0)

0.003
0.02
0.7
0.08
0.23

Recommended treatment duration, wks,
median (IQR)

6 (4–6)

6 (4–6)

0.32

Variable, n (%)
Initial antistaphylococcal therapyc
Vancomycin
Daptomycin
Linezolid
Ceftaroline
Cefazolin
Ceftriaxone
Antistaphylococcal penicillin
No antibiotics

aPreimplementation

period from 1 January 2018 to 13 January 2019.
period from 14 January 2019 to 31 December 2019.
cAntibiotic therapy within the day of index blood culture.
dAntibiotic therapy at discharge or ﬁnal infectious diseases recommendations.

out that instrument detection algorithms and constant incubation temperature were
also contributing factors.
We also observed a faster TTP with the new blood culture system, and this was
almost unchanged on the following repeat positive blood cultures, despite antibiotic
therapy. Previously, other studies have observed a decreased TTP using Virtuo compared to that using other blood culture systems using simulated samples inoculated
with different concentrations of microorganisms (11, 14, 15, 17, 18, 24), including that
using VersaTREK system (8). In our cohort, neither SAB duration nor TTP in the index
blood culture was associated with mortality at 90 days. Other studies have found TTP
to be associated with increased mortality (6, 25); however, they used blood culture systems (Bactec FX [Becton, Dickinson; BD] and Bactec 9240 [BD]/BacT/Alert [bioMérieux],
respectively) different from those used in our study. Our ﬁndings suggest that the
observed duration of SAB and faster TTP represented characteristics of the blood culture systems and not necessarily the severity of the SAB. Further studies should take
into consideration the blood culture system being used when assessing duration of
bacteremia and TTP positivity as clinical predictors of SAB outcomes.
Clinical guidelines recommend that persistent bacteremia of 7 days should prompt
an assessment to change therapy if indicated (26), based on older studies in which a
median time of 7 days of bacteremia was expected for clearance in patients with MRSA
and infective endocarditis (27). More recently, a study reported that each additional
day of bacteremia was associated with adverse outcomes, including mortality, and suggested changes in management if bacteremia persisted for 3 or more days (3). None of
these studies, however, speciﬁed what blood culture system or media they used. We
found that implementation of a new blood culture system affected the duration of
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TABLE 4 Predictors for 90-day mortality from initial positive blood culture among 416 Staphylococcus aureus bacteremia episodesa
Survived (n = 282)
56 (39–67)
173 (61)
5 (3–8)
131 (46)
158 (56)
114 (40)
196 (70)
163 (58)

Died (n= 134)
62.5 (51–71)
76 (57)
6 (3–8)
63 (47)
73 (54)
54 (40)
87 (65)
77 (57)

Crude OR (95% CI)
1.03 (1.01–1.04)
0.83 (0.54–1.25)
1.02 (0.96–1.09)
1.02 (0.68–1.54)
0.94 (0.62–1.42)
0.99 (0.65–1.51)
0.81 (0.53–1.26)
0.98 (0.65–1.5)

Site of infection
Isolated bacteremia
Central line-associated bacteremia
Skin and soft tissue infection
Osteomyelitis
Septic arthritis
Epidural abscess
Endocarditis
Vascular graft infection
Lower respiratory tract infection
Cardiac device associated infection

59 (21)
61 (22)
34 (12)
43 (15)
23 (8)
10 (4)
45 (16)
7 (2)
23 (8)
14 (5)

29 (22)
37 (28)
20 (15)
11 (8)
5 (4)
3 (2)
23 (17)
7 (5)
23 (17)
6 (4)

1.04 (0.63–1.72)
1.38 (0.86–2.22)
1.28 (0.71–2.32)
0.5 (0.25–1)
0.44 (0.16–1.17)
0.62 (0.17–2.3)
1.09 (0.63–1.89)
2.17 (0.74–6.3)
2.33 (1.26–4.33)
0.9 (0.34–2.39)

Bacteremia duration, intermediate/prolonged ($3 days)
Time to positivity of index BC, hours
Source removed/controlled
Time from index BC to source control, days

116 (41)
16 (12–21)
141 (50)
3 (1–6)

61 (46)
14 (11–20)
50 (37)
3.5 (1–6)

1.2 (0.79–1.81)
1 (0.99–1.02)
0.6 (0.39–0.91)
1.02 (0.97–1.07)

Initial antistaphylococcal therapy
Vancomycin
Daptomycin
Linezolid
Cefazolin
Antistaphylococcal penicillin

230 (82)
6 (2)
11 (4)
6 (2)
6 (2)

100 (75)
1 (1)
10 (7)
3 (2)
2 (1)

0.66 (0.41–1.09)
0.35 (0.04–2.9)
1.99 (0.82–4.8)
1.05 (0.26–4.3)
0.7 (0.14–3.5)

Deﬁnitive antistaphylococcal therapy
Vancomycin
Daptomycin
Linezolid
Cefazolin
Antistaphylococcal penicillin
Ceftriaxone
Combination antistaphylococcal therapy

74 (26)
39 (14)
5 (2)
58 (21)
50 (18)
54 (19)
29 (10)

39 (29)
16 (12)
8 (6)
27 (20)
18 (13)
25 (19)
20 (15)

1.15 (0.73–1.82)
0.84 (0.45–1.57)
3.52 (1.13–10.97)
0.97 (0.58–1.63)
0.72 (0.4–1.29)
0.97 (0.57–1.64)
1.53 (0.83–2.82)

Adjusted ORb (95% CI)
1.03 (1.02–1.05)

0.43 (0.21–0.89)

2.2 (1.13–4.11)

3.79 (1.15–12.51)

aIQR,

interquartile range; OR, odds ratio; CI, conﬁdence intervals; BC, blood culture; ICU, intensive care unit; MRSA, methicillin-resistant S. aureus.
included for consideration in the logistic regression model were age, osteomyelitis, lower respiratory tract infection, source removed/controlled, and linezolid use
as deﬁnitive antistaphylococcal therapy.

bVariables

bacteremia without changes in clinical outcomes but did affect management of SAB.
Combination therapy in SAB is still controversial, with studies showing time to clearance of blood cultures shorter than that of monotherapy but no signiﬁcant mortality
beneﬁt (4, 28). It is possible that these studies may have inﬂuenced our ID physicians’
practice, causing increased use of combination therapy during the postimplementation period; however, the observed shorter time to source control and the increased
ordering of FDG-PET/CT scans suggest a more aggressive overall approach with the
longer observed duration of bacteremia during the postimplementation period.
Similarly, although a longer time to source control has been associated with prolonged
bacteremia (3), in our study the overall time to source control was shorter in the postimplementation period. This may be due to the longer observed SAB duration, increasing the perceived need for source control by the treating physicians.
Our study has some limitations. First, this is a single-center, retrospective study, and
it may not be representative of other hospitals. However, our 90-day mortality was similar to that of a previous study (29), and the 30-day mortality (15%) was also similar to
that of other studies (30, 31). Second, our institution previously used the VersaTREK
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Variable, n (%) or median (IQR)
Age, yrs
Sex, male
Charlson comorbidity index
ICU admission within 48 h of index BC
ICU admission during hospitalization
MRSA bacteremia
Bacteremia onset, community-onset
Postimplementation period
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system, which may not be used at other institutions, and implementation of a new
blood culture system may not have the same effect as that seen in our cohort.
However, our study raises the important consideration of increased detection of organisms on subsequent blood cultures when implementing newer blood culture systems
and the possibility of this affecting patient management. Third, we could not account
for all potential factors affecting performance of a blood culture system, such as blood
volume for each blood culture bottle collected, transport time to the laboratory, number of participants with polymicrobial bacteremia or those that had blood culture
obtained from a central line catheter, or the timing/level of antibiotic prior to blood
culture collection. Yet, we accounted for the number and frequency of blood culture
bottles collected, and we did not observe an increase in blood volume per bottle during the postimplementation period in the small, random subset of bottles analyzed as
part of laboratory quality assurance (data not shown). Fourth, we cannot account for
other potential temporal factors that may have inﬂuenced SAB management in the
postimplementation period, such as newer publications of combination therapy and
usefulness of imaging modalities; however, no new SAB clinical guidelines have been
published since 2011, and no changes in institution guidelines or blood culture collection practices were instituted between both periods in our study. Finally, due to the
observational design, we cannot account for unmeasured confounding factors that
may have inﬂuenced our ﬁnal mortality prediction model.
Conclusion. We found that implementation of a new blood culture system was associated with an observed increase in prolonged SAB, likely from the blood culture media,
and changes in the ID physicians’ clinical approach toward SAB but was not associated
with worsening clinical outcomes. ID physicians and future clinical guidelines should
consider the blood culture system used at their institution when assessing bacteremia
duration and TTP in their decision-making process for the treatment of SAB.
SUPPLEMENTAL MATERIAL
Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF ﬁle, 0.1 MB.

1. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB.
2012. Predictors of mortality in Staphylococcus aureus bacteremia. Clin
Microbiol Rev 25:362–386. https://doi.org/10.1128/CMR.05022-11.
2. Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG, Jr. 2015. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev 28:603–661. https://doi
.org/10.1128/CMR.00134-14.
3. Minejima E, Mai N, Bui N, Mert M, Mack WJ, She RC, Nieberg P, Spellberg
B, Wong-Beringer A. 2020. Deﬁning the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes. Clin Infect Dis 70:
566–573. https://doi.org/10.1093/cid/ciz257.
4. Tong SYC, Lye DC, Yahav D, Sud A, Robinson JO, Nelson J, Archuleta S,
Roberts MA, Cass A, Paterson DL, Foo H, Paul M, Guy SD, Tramontana AR,
Walls GB, McBride S, Bak N, Ghosh N, Rogers BA, Ralph AP, Davies J,
Ferguson PE, Dotel R, McKew GL, Gray TJ, Holmes NE, Smith S, Warner MS,
Kalimuddin S, Young BE, Runnegar N, Andresen DN, Anagnostou NA,
Johnson SA, Chatﬁeld MD, Cheng AC, Fowler VG, Howden BP, Meagher N,
Price DJ, van Hal SJ, O'Sullivan MVN, Davis JS, Australasian Society for Infectious Diseases Clinical Research Network. 2020. Effect of vancomycin
or daptomycin with vs without an antistaphylococcal b -lactam on mortality, bacteremia, relapse, or treatment failure in patients with MRSA bacteremia: a randomized clinical trial. JAMA 323:527–537. https://doi.org/10
.1001/jama.2020.0103.
5. Siméon S, Le Moing V, Tubiana S, Duval X, Fournier D, Lavigne J-P,
Erpelding M-L, Gustave C-A, Desage S, Chirouze C, Vandenesch F, Tattevin
P, Chirouze C, Curlier E, Descottes-Genon C, Hoen B, Patry I, Vettoretti L,
Chavanet P, Eicher J-C, Gohier-Treuvelot S, Greusard M-C, Neuwirth C,
Péchinot A, Piroth L, Célard M, Cornu C, Delahaye F, Hadid M, Rausch P,
Coma A, Galtier F, Géraud P, Jean-Pierre H, Le Moing V, Sportouch C,
Reynes J, Aissa N, Doco-Lecompte T, Goehringer F, Keil N, Letranchant L,
Malela H, May T, Selton-Suty C, Bedos N, Lavigne J-P, Lechiche C, Sotto A,
April 2022 Volume 60 Issue 4

6.

7.

8.

9.

10.

11.

12.

Duval X, et al. 2019. Time to blood culture positivity: an independent predictor of infective endocarditis and mortality in patients with Staphylococcus aureus bacteraemia. Clin Microbiol Infect 25:481–488. https://doi
.org/10.1016/j.cmi.2018.07.015.
Kahn F, Resman F, Bergmark S, Filiptsev P, Nilson B, Gilje P, Rasmussen M.
2020. Time to blood culture positivity in Staphylococcus aureus bacteremia is useful to determine the risk for infective endocarditis. Clin Microbiol Infect 27:1345.e7–1345.e12. https://doi.org/10.1016/j.cmi.2020.11
.007.
Lamy B. 2019. Blood culture time-to-positivity: making use of the hidden
information. Clin Microbiol Infect 25:268–271. https://doi.org/10.1016/j
.cmi.2018.12.001.
Yarbrough ML, Wallace MA, Burnham CD. 2021. Comparison of microorganism detection and time to positivity in pediatric and standard media
from three major commercial continuously monitored blood culture systems. J Clin Microbiol 59:e0042921. https://doi.org/10.1128/JCM.00429-21.
Lamy B, Sundqvist M, Idelevich EA, ESCMID Study Group for Bloodstream
Infections, Endocarditis and Sepsis (ESGBIES). 2020. Bloodstream infections standard and progress in pathogen diagnostics. Clin Microbiol Infect 26:
142–150. https://doi.org/10.1016/j.cmi.2019.11.017.
Chavez MA, Munigala S, Burnham CD, Yarbrough ML, Warren DK. 2021.
Real-world evaluation of the impact of implementation of the virtuo blood
culture system in a tertiary care hospital. J Clin Microbiol 59:e0061721.
https://doi.org/10.1128/JCM.00617-21.
Totty H, Ullery M, Spontak J, Viray J, Adamik M, Katzin B, Dunne WM, Deol
P. 2017. A controlled comparison of the BacT/ALERT 3D and VIRTUOTM microbial detection systems. Eur J Clin Microbiol Infect Dis 36:1795–1800.
https://doi.org/10.1007/s10096-017-2994-8.
Ransom EM, Alipour Z, Wallace MA, Burnham CA. 2021. Evaluation of optimal blood culture incubation time to maximize clinically relevant results
10.1128/jcm.02261-21

9

Downloaded from https://journals.asm.org/journal/jcm on 02 June 2022 by 128.252.16.235.

REFERENCES

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

from a contemporary blood culture instrument and media system. J Clin
Microbiol 59 https://doi.org/10.1128/JCM.02459-20.
Hawkins C, Huang J, Jin N, Noskin GA, Zembower TR, Bolon M. 2007. Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 167:1861–1867. https://doi.org/10.1001/archinte
.167.17.1861.
Menchinelli G, Liotti FM, Fiori B, De Angelis G, D'Inzeo T, Giordano L,
Posteraro B, Sabbatucci M, Sanguinetti M, Spanu T. 2019. In vitro evaluation of BACT/ALERT(R) VIRTUO(R), BACT/ALERT 3D(R), and BACTEC FX
automated blood culture systems for detection of microbial pathogens
using simulated human blood samples. Front Microbiol 10:221. [PMC] .
https://doi.org/10.3389/fmicb.2019.00221.
Kim SC, Lee S, Kim S, Cho OH, Park H, Yu SM. 2019. Comparison of clinical performance between BacT/Alert Virtuo and BacT/Alert 3D blood culture systems. Ann Lab Med 39:278–283. https://doi.org/10.3343/alm.2019.39.3.278.
Jacobs MR, Mazzulli T, Hazen KC, Good CE, Abdelhamed AM, Lo P, Shum
B, Roman KP, Robinson DC. 2017. Multicenter clinical evaluation of BacT/
Alert Virtuo blood culture system. J Clin Microbiol 55:2413–2421. https://
doi.org/10.1128/JCM.00307-17.
Altun O, Almuhayawi M, Lüthje P, Taha R, Ullberg M, Özenci V. 2016. Controlled evaluation of the new BacT/Alert Virtuo blood culture system for
detection and time to detection of bacteria and yeasts. J Clin Microbiol
54:1148–1151. https://doi.org/10.1128/JCM.03362-15.
Somily AM, Habib HA, Torchyan AA, Sayyed SB, Absar M, Al-Aqeel R,
Binkhamis AK. 2018. Time-to-detection of bacteria and yeast with the
BACTEC FX versus BacT/Alert Virtuo blood culture systems. Ann Saudi
Med 38:194–199. https://doi.org/10.5144/0256-4947.2018.194.
Park J, Han S, Shin S. 2017. Comparison of growth performance of the
BacT/ALERT VIRTUO and BACTEC FX blood culture systems under simulated bloodstream infection conditions. Clin Lab 63:39–46. https://doi
.org/10.7754/Clin.Lab.2016.160502.
Congestrì F, Pedna MF, Fantini M, Samuelli M, Schiavone P, Torri A, Bertini
S, Sambri V. 2017. Comparison of 'time to detection' values between
BacT/ALERT VIRTUO and BacT/ALERT 3D instruments for clinical blood
culture samples. Int J Infect Dis 62:1–5. https://doi.org/10.1016/j.ijid.2017
.06.012.
Li G, Sun J, Pan S, Li W, Zhang S, Wang Y, Sun X, Xu H, Ming L. 2019. Comparison of the performance of three blood culture systems in a Chinese
tertiary-care hospital. Front Cell Infect Microbiol 9:285. https://doi.org/10
.3389/fcimb.2019.00285.
Miller NS, Rogan D, Orr BL, Whitney D. 2011. Comparison of BD Bactec
Plus blood culture media to VersaTREK Redox blood culture media for
detection of bacterial pathogens in simulated adult blood cultures

April 2022 Volume 60 Issue 4

Journal of Clinical Microbiology

23.

24.

25.

26.

27.

28.

29.

30.

31.

containing therapeutic concentrations of antibiotics. J Clin Microbiol 49:
1624–1627. https://doi.org/10.1128/JCM.01958-10.
Lovern D, Katzin B, Johnson K, Broadwell D, Miller E, Gates A, Deol P,
Doing K, van Belkum A, Marshall C, Mathias E, Dunne WM. 2016. Antimicrobial binding and growth kinetics in BacT/ALERT FA Plus and BACTEC
Aerobic/F Plus blood culture media. Eur J Clin Microbiol Infect Dis 35:
2033–2036. https://doi.org/10.1007/s10096-016-2759-9.
Chung Y, Kim I-H, Han M, Kim HS, Kim H-S, Song W, Kim J-S. 2019. A comparative evaluation of BACT/ALERT FA PLUS and FN PLUS blood culture
bottles and BD BACTEC Plus aerobic and anaerobic blood culture bottles
for antimicrobial neutralization. Eur J Clin Microbiol Infect Dis 38:
2229–2233. https://doi.org/10.1007/s10096-019-03663-3.
Khatib R, Riederer K, Saeed S, Johnson LB, Fakih MG, Sharma M, Tabriz
MS, Khosrovaneh A. 2005. Time to positivity in Staphylococcus aureus
bacteremia: possible correlation with the source and outcome of infection. Clin Infect Dis 41:594–598. https://doi.org/10.1086/432472.
Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL,
Karchmer AW, Levine DP, Murray BE, J Rybak M, Talan DA, Chambers HF,
Infectious Diseases Society of America. 2011. Clinical practice guidelines
by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.
Clin Infect Dis 52:e18-55. https://doi.org/10.1093/cid/ciq146.
Levine DP, Fromm BS, Reddy BR. 1991. Slow response to vancomycin or
vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus
endocarditis. Ann Intern Med 115:674–680. https://doi.org/10.7326/0003
-4819-115-9-674.
Kale-Pradhan PB, Giuliano C, Jongekrijg A, Rybak MJ. 2020. Combination
of vancomycin or daptomycin and beta-lactam antibiotics: a meta-analysis. Pharmacotherapy 40:648–658. https://doi.org/10.1002/phar.2437.
Hanses F, Spaeth C, Ehrenstein BP, Linde HJ, Schölmerich J, Salzberger B.
2010. Risk factors associated with long-term prognosis of patients with
Staphylococcus aureus bacteremia. Infection 38:465–470. https://doi.org/
10.1007/s15010-010-0059-3.
Turnidge JD, Kotsanas D, Munckhof W, Roberts S, Bennett CM, Nimmo
GR, Coombs GW, Murray RJ, Howden B, Johnson PDR, Dowling K, Australia New Zealand Cooperative on Outcomes in Staphylococcal Sepsis.
2009. Staphylococcus aureus bacteraemia: a major cause of mortality in
Australia and New Zealand. Med J Aust 191:368–373. https://doi.org/10
.5694/j.1326-5377.2009.tb02841.x.
Benﬁeld T, Espersen F, Frimodt-Møller N, Jensen AG, Larsen AR, Pallesen LV,
Skov R, Westh H, Skinhøj P. 2007. Increasing incidence but decreasing inhospital mortality of adult Staphylococcus aureus bacteraemia between
1981 and 2000. Clin Microbiol Infect 13:257–263. https://doi.org/10.1111/j
.1469-0691.2006.01589.x.

10.1128/jcm.02261-21

10

Downloaded from https://journals.asm.org/journal/jcm on 02 June 2022 by 128.252.16.235.

S. aureus Bacteremia with Two Blood Culture Systems

